Alice joined Purespring in 2022. Prior to this, Alice was a Senior Director in the department of Cell Therapy Innovation at Takeda Pharmaceuticals following the acquisition by Takeda of GammaDelta Therapeutics in 2021, where Alice had held the role of VP Research and, before that, VP Gene Engineering.

At GammaDelta Alice built and led the research team and was responsible for developing multiple cell therapy programmes from discovery through to completion of pre-clinical development. Alice joined GammaDelta from PsiOxus Therapeutics where she was the Director of Biology.

Alice holds a degree and PhD in Biochemistry from the University of Bristol and carried out her post-doctoral research in Immunology at Imperial College London.

Fredrik joined Purespring in 2023 as an experienced developer of novel nephrology drugs, having worked in all phases of drug development and medical affairs across large pharma and biotech.

Prior to Purespring, Fredrik served as Head Global Clinical Development at CSL Vifor. He has previously held positions within the clinical development teams at AstraZeneca, Bayer, and Antisoma.

He holds a medical degree and PhD from Karolinska Institutet in Stockholm, Sweden.

Peter joined Purespring in 2023 and is focused on ensuring our people can thrive at work by creating inclusive experiences and a culture to deliver our ambition for patients. He has over 25 years’ experience and expertise linking people and business strategies across a broad range of HR including talent management, culture transformation and strategic organisation design and development.

Prior to Purespring, Peter worked at GSK, where he held various roles including: VP HR; VP Talent, Learning and OD and Global Head of Coaching & Organisation Development. Prior to that he was Head of Leadership Development at AXA.

Peter holds a BSc in IT and Management from Birkbeck, University of London, is a certified OD Practitioner from the NTL Institute for Applied Behavioural Science and a CIPD accredited executive coach with Oxford Brooks University.

Nick joined Purespring in 2025. With over a decade of biopharma and healthcare expertise, Nick has an extensive background in defining and executing on strategic opportunities, bringing a comprehensive skillset at the intersection of science and finance.

Prior to Purespring, Nick recently served as an Executive Director in the healthcare investment banking team at Morgan Stanley, supporting companies in creating their equity story, raising public and private capital and executing on M&A and licensing activities. He has an in-depth knowledge of the biopharma landscape, with a particular focus on companies in the cardio-metabolic, rare disease and immunology spaces.

Nick worked as a medical doctor at Barts in London and brings strategy experience from McKinsey & Co. He was a visiting fellow in value-based care at the Institute for Strategy and Competitiveness at Harvard Business School.
Nick holds a MBChB in Medicine and Surgery from the University of Bristol and an MBA from London Business School, where he also taught strategy on the Masters in Management programme.

Robert is responsible for our global regulatory strategy, partnering with the Regulatory Authorities and utilising accelerated pathways, to advance our innovative products so that they are available to patients at the earliest opportunity.  He brings more than 25 years’ experience working in Regulatory Affairs across all stages of clinical development and post-licensing.

Prior to working at Purespring, Robert held leadership roles within the regulatory affairs teams of both biotech and large pharma companies, including Jazz Pharmaceuticals, Nightstar (acquired by Biogen), Shire (acquired by Takeda) and Parexel Consulting.

Robert holds a BSs (Hons) in Biotechnology and Management from Southbank University, London and a Diploma in Regulatory Affairs.

Amanda is responsible for the establishment & delivery of Purespring’s AAV vector manufacturing, critical starting materials supply & analytical methods for Purespring’s products from tox through to late-stage clinical trials production & commercialisation. She brings more than 29 years of industrial experience in biological product development, GMP manufacturing and analysis.

Prior to Purespring, Amanda has held CMC scientific & leadership roles in both product development companies and CDMOs, including Nightstar (acquired by Biogen), Fujifilm Diosynth Biotechnologies, UCB, Renovo (acquired by Shire) & Cobra Biologics (acquired by Charles River Laboratories).

She holds a MSc(Eng) in Biochemical Engineering from the University of Birmingham. Amanda is a registered Chartered Engineer and elected member of IChemE (Fellows).

John Tsai is Chief Executive Officer of Forcefield Therapeutics and an Executive Partner of Syncona Investment Management Ltd.

John manages organisational leadership and strategy as CEO of Forcefield Therapeutics. He is also an Executive Partner at Syncona Investment Management Ltd, where he supports the strategic execution of new and existing opportunities. He brings 20 years’ leadership experience in bringing innovative therapies to market across the globe.

As President, Global Drug Development and Chief Medical officer at Novartis, John led the Company’s development portfolio for 4 years. Before joining Novartis, John was Chief Medical Officer and Senior Vice President of Global Medical Affairs at Amgen and spent 11 years at Bristol Myers Squibb, where he had roles in the Medical and Drug Development organizations.

A trained physician, John received his medical degree from the University of Louisville School of Medicine and a Bachelor of Science in Electrical Engineering from Washington University in St. Louis.

Haseeb is the CEO of Purespring Therapeutics. Haseeb joined Purespring in March 2025, bringing over 25 years of experience in the life sciences industry, successfully leading organisations to create blockbuster brands, from primary care to rare diseases in both mature and growth markets.

Prior to Purespring, Haseeb served as President of Novartis Europe, where he oversaw $15 billion in revenue across 53 markets. Prior to this he led Novartis Gene Therapies to bring first class gene therapies to patients. Haseeb also held numerous global and in country leadership roles at both Novartis and Merck & Co.

Haseeb also served as President and Chairman of the Board for the Association of the British Pharmaceutical Association and is currently Non-executive Director and Trustee at Health Data Research UK.

Maina is a Partner in the Sofinnova Capital Strategy.

Maina joined Sofinnova Partners in 2018, bringing an extensive network and a long track record as a successful healthcare investor. Prior to joining Sofinnova, she was director of healthcare investment at Touchstone Innovations (formerly Imperial Innovations) in London, where she led and co-led investments in the UK.

Before turning to investing, Maina worked in the R&D teams of several UK and US biotech companies, including Celltech, Oxford GlycoSciences, Chimeric Therapies and GeneMedicine.

Maina holds a BSc from the University of Texas at Austin and an MBA from the Imperial Business School.

Sonia is an Investment Manager at Gilde Healthcare, focusing on venture and growth capital investments in the therapeutic and healthtech sectors.

Prior to Gilde, Sonia was a Vice President at EQT Life Sciences (and formerly LSP) dedicated to the firm’s flagship therapeutics-focused venture funds. She held board positions on Evommune, ViCentra, and NOBI, and was heavily involved in numerous investments in private therapeutics and medtech companies.

Prior to EQT, Sonia founded two start-ups, focused in digital health and infectious disease diagnostics. Before her entrepreneurial work, she was a strategy consultant within Accenture’s life sciences practice, based in the London office.

Sonia holds a BEng in Chemical Engineering from McGill University and an MSc in Biotechnology from the Swiss Federal Institute of Technology Lausanne (EPFL). She completed her PhD with Dame Molly Stevens at Imperial College London, where she developed induced pluripotent stem (iPS) cell-based regenerative medicines.

Marco is a General Partner at Forbion and joined the team in 2007.

He has a special interest in bringing his biotechnology, operations, business development, and investment experience from both small and large businesses to the portfolio, and to establish and manage new companies as part of Forbion’s build strategy. He was the founding CEO of VectorY Therapeutics and instrumental in the launch and financing of multiple “Forbion build” companies. He has served on the boards of several pre- and clinical-stage companies in Europe and North America, a number of which have been either acquired for over a billion bio-dollars or listed on Nasdaq.

Before joining Forbion, Marco was Business Development Director at DSM Pharmaceutical Products, managing biomanufacturing technologies and contract manufacturing projects, and he developed manufacturing processes for biosimilars at Cytos Biotechnology.

Marco has an MSc in Molecular Biology from the University of Groningen and holds a PhD in Biotechnology from the ETH Institute of Technology in Zürich, Switzerland.

Chris is the Chief Executive Officer of Syncona Investment Management Ltd.

He has been instrumental in the foundation and development of Syncona’s gene therapy strategy, where it has founded companies focused on the eye, the liver, the kidney, and central nervous system. He is Chairman of Spur, and is a Board member of Beacon and Yellowstone. He was also previously Chairman of Purespring and retinal gene therapies Nightstar, which was sold to Biogen in 2019 for $877 million, and Gyroscope, which was sold to Novartis for $800 million in 2022.

Previously, Chris was a partner of Apposite Capital LLP, a venture and growth capital healthcare investment company. Before Apposite, Chris had roles with Bioscience Managers Ltd, Neptune Investment Management Ltd and in the pharmaceutical industry. Chris holds a degree in Natural Sciences and a PhD in Organic Chemistry, both from the University of Cambridge.

Richard Francis is the CEO of Teva Pharmaceutical Industries Ltd.

He led Purespring Therapeutics as CEO from 2021 through to the end of 2022 and remains an active Board member.
Prior to this, Richard was the CEO of Sandoz, a global leader in generics and biosimilars. He was also a member of the Executive Committee of Novartis Sandoz.

Richard joined Novartis from Biogen Idec, where he was most recently Senior Vice President of US Commercial. Prior to this role and during his 13-year career at the company, he was the Head of Global Strategy and Marketing, Managing Director of Canada, and Managing Director of the UK & Ireland.

From 1998 to 2001, Richard was at Sanofi in the UK and held various marketing roles across the company’s urology, analgesics and cardiovascular products. He also held sales and marketing positions at Lorex Synthelabo and Wyeth.
Richard received a B.A. in Economics from Manchester Metropolitan University in the UK.

Moin is Professor of Paediatric Renal Medicine at the University of Bristol and Director of Bristol Renal, a glomerular research group of approximately 45 researchers, covering all areas from cell biology, transgenic models and population cohorts and genetics.

Moin is the originator of the gold-standard human podocyte cell lines, used worldwide for academic and industry research. Moin also set up the UK Renal Rare Disease Registry (RaDaR) and is currently leading the UK nephrotic syndrome study (NephroS), as well as a major industry-academic collaboration termed NURTuRE (National Unified Renal Translational Research Enterprise).

Moin trained as an undergraduate at University College, London, and is a Fellow of the Royal College of Physicians. His PhD was in transplantation immunology at the Institute of Child Health, London, followed by Paediatric Nephrology training at Great Ormond Street Hospital, London.